HC Wainwright Reaffirms Buy Rating for Omeros Corporation
HC Wainwright maintains its buy rating on Omeros with a $33 price target, a 233% upside from the current price.
Key Points
- On June 26, 2026, HC Wainwright reiterated its buy rating for Omeros Corporation (OMER) with a price target of $33.
- HC Wainwright's $33 price target implies 233% upside from Omeros Corporation's ($OMER) current $9.91 share price.
- Shares of Omeros traded at $10.72 on Friday, with a market cap of approximately $775.9 million and a P/E ratio of 9.4.
- BlackRock, Inc. increased its Omeros holdings by 247,188 shares, totaling 5,309,626 shares valued at about $56.1 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright & Co. has reaffirmed its buy rating for Omeros Corporation (NasdaqGM: OMER) as of June 26, 2026. The firm set a price target of $33, indicating confidence in the company's potential upside. Shares of Omeros were trading at $10.72 on Friday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Omeros Corporation Stock Down 46.7%
Shares of NasdaqGM:OMER traded near $10.72 on Friday. Omeros Corporation, with a market cap of approximately $775.9 million, has a price-to-earnings ratio of 9.4. The company's stock has experienced a 52-week low of $2.95 and a high of $17.65. Its 50-day moving average is $12.13, while the 200-day moving average stands at $10.23. Omeros also maintains a current ratio of 3.03 and a quick ratio of 2.48, reflecting its solid liquidity position.
$OMER price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Other Institutional Activity in Omeros Corporation
BlackRock, Inc. increased its holdings in Omeros by 247,188 shares, ending with a total of 5,309,626 shares valued at about $56.1 million, marking a 4.9% increase. Ingalls & Snyder LLC also boosted its position by 110,724 shares, bringing its total to 3,559,423 shares worth roughly $37.6 million, a 3.2% increase. Vanguard Capital Management LLC opened a new position in Omeros with 2,983,259 shares valued at approximately $31.5 million. UBS Group AG added 117,749 shares, resulting in a 5.3% increase, with a total of 2,340,731 shares worth about $24.7 million. State Street Corp grew its stake by 346,049 shares, a 22% increase, reaching 1,919,575 shares valued at $20.3 million.
Insider Buying and Selling at Omeros Corporation
Several insiders made significant stock purchases on June 18, 2026. Leroy Hood, MD, PhD, Diana Perkinson, Rajiv Shah, Thomas Bumol, Arnold Hanish, and Peter Demopulos, MD each acquired 15,000 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
On June 26, 2026, HC Wainwright & Co. maintained its buy rating on Omeros Corporation with a price target of $33. The consensus among analysts is a buy rating, with a mean price target of $40 based on the opinions of one analyst.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company based in Seattle, Washington. It focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for immunologic diseases. The company is led by CEO Dr. Gregory A. Demopulos and employs around 175 people. Omeros is working on several clinical-stage products, including Narsoplimab for stem-cell transplant-associated thrombotic microangiopathy and other conditions, as well as other therapeutics for various disorders.
Bottom Line
HC Wainwright's reaffirmation of a buy rating with a $33 target price highlights confidence in Omeros Corporation's growth potential. Investors often track analyst ratings for insights into a stock's future performance. It's important to note that these ratings reflect the analysts' views at the time and may not represent current market conditions.
Get Omeros Corporation alerts
New 13F filings, insider trades, and analyst moves on $OMER, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.